Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers

Added 250 days ago (19.01.2021)
Authors: Jhaveri, K., Chang, M. T., Juric, D., Saura, C., Gambardella, V., Melnyk, A., Patel, M. R., Ribrag, V., Ma, C. X., Aljumaily, R., Bedard, P. L., Sachdev, J. C., Dunn, L., Won, H., Bond, J., Jones, S., Savage, H. M., Scaltriti, M., Wilson, T. R., Wei, M. C., Hyman, D. M.
Read article